EU/3/15/1510: Orphan designation for the treatment of amyotrophic lateral sclerosis
Table of contents
On 19 June 2015, orphan designation (EU/3/15/1510) was granted by the European Commission to Mitsubishi Tanabe Pharma Europe Ltd, United Kingdom, for edaravone for the treatment of amyotrophic lateral sclerosis.
The sponsorship was transferred to Mitsubishi Tanabe Pharma GmbH, Germany, in March 2019.
Treatment of amyotrophic lateral sclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Mitsubishi Tanabe Pharma GmbH
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: